SynthesisJournal of global health2026
National, regional and provincial prevalence of peripheral artery disease in Chinese adults in 2023: an updated systematic review and modelling study.
Synthesis in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretable machine learning and mendelian randomization identify risk factors for lower extremity arterial embolism and thrombosis.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peripheral artery disease (PAD), a common atherosclerotic condition characterised by the narrowing or obstruction of peripheral arteries, has become a substantial public health concern in China. However, its prevalence across the country at the provincial level has never been quantified. Through an updated systematic review and modelling study, we aimed to estimate the national, regional, and provincial prevalence of PAD among Chinese individuals aged 30-89 years in 2023. Methods: We conducted an updated literature search in PubMed, Embase, MEDLINE, the China National Knowledge Infrastructure, Wanfang, and the Chinese Science and Technology Journal Database to identify studies published between 4 March 2017 and 12 August 2024 reporting on the prevalence of PAD in the general Chinese population. We also identified and included studies from previous systematic reviews. We then used a multilevel mixed-effects meta-regression model to generate the age- and sex-specific prevalence estimates of PAD among individuals aged 30-89 years at the national level. We calculated pooled odds ratios (ORs) for factors associated with PAD using a random-effects meta-analysis and incorporated them into an 'associated factor-based model' to estimate regional and provincial prevalence. Results: We included 54 articles from all searches. Model-based estimates indicated that the overall prevalence of PAD among Chinese adults aged 30-89 years in 2023 was 5.47% (95% confidence interval (CI) = 4.64-6.44), equivalent to 49.90 million (95% CI = 42.32-58.73) affected individuals. Prevalence increased progressively with age, ranging from 4.23% (95% CI = 3.58-5.00) among individuals aged 30-34 years to 18.37% (95% CI = 15.90-21.13) among those aged 85-89 years. The overall prevalence was higher in females (6.19%; 95% CI = 5.25-7.27) than males (4.76%; 95% CI = 4.03-5.61). Regionally, Northeast China had the highest prevalence of PAD at 5.87% (95% CI = 4.98-6.91), while Central China had the lowest at 5.26% (95% CI = 4.46-6.19). At the provincial level, the prevalence of PAD was the highest in Beijing (6.40%; 95% CI = 5.43-7.53) and lowest in Tibet (4.35%; 95% CI = 3.68-5.12). Female sex, current smoking, hypertension, diabetes, coronary heart disease, and stroke were identified as factors significantly associated with PAD. Conclusions: We found that PAD is prevalent in China, with pronounced age-related trends, sex differences, and regional disparities. These findings could inform targeted public health initiatives and appropriate resource allocation. Registration: PROSPERO: CRD420251118923.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.